Buscar
Annovis Bio Inc
ANVSAñadir a la lista de seguimiento
1.660USD
-0.095-5.43%
Cierre 07-24 16:00（ET）Cotizaciones retrasadas 15 min
33.51MCap. mercado
PérdidaP/E TTM
Más Datos de Annovis Bio Inc Compañía
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Información de Annovis Bio Inc
Símbolo de cotizaciónANVS
Nombre de la empresaAnnovis Bio Inc
Fecha de salida a bolsaJan 29, 2020
Director ejecutivoMaccecchini (Maria L)
Número de empleados8
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 29
Dirección101 Lindenwood Drive, Suite 225
CiudadMALVERN
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal19355
Teléfono14848753192
Sitio Webhttps://www.annovisbio.com/
Símbolo de cotizaciónANVS
Fecha de salida a bolsaJan 29, 2020
Director ejecutivoMaccecchini (Maria L)
Ejecutivos de Annovis Bio Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.72M
+4.45%
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Dr. Cheng Fang, Ph.D.
Dr. Cheng Fang, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Ms. Eve Damiano
Ms. Eve Damiano
Senior Vice President - Regulatory
Senior Vice President - Regulatory
--
--
Ms. Melissa Gaines
Ms. Melissa Gaines
Senior Vice President - Clinical Operations
Senior Vice President - Clinical Operations
--
--
Dr. Mike Christie, Ph.D.
Dr. Mike Christie, Ph.D.
Vice President - Process Chemistry
Vice President - Process Chemistry
--
--
Mr. Mark P. Guerin, CPA
Mr. Mark P. Guerin, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.72M
+4.45%
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Dr. Cheng Fang, Ph.D.
Dr. Cheng Fang, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Annovis Bio Inc?
Los cinco principales accionistas de Annovis Bio Inc son: Mr. Michael B. Hoffman
¿Cuántas instituciones poseen acciones de Annovis Bio Inc (ANVS)?
A fecha de 2026Q1, 109 instituciones poseen acciones de Annovis Bio Inc, con un valor de mercado combinado de aproximadamente 5.17M, lo que representa el 14.92% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1139662.00.